Business and Finance

Will employer benefit plans lose their enthusiasm for PBMs?

Revenues and earnings were up for the year; stock jumps 8.8% in the day

McKesson disappoints on Q2 earnings call; stock drops 23%. Update: Cardinal reports more revenue, less profit

Price growth is less than branded growth, but higher than inflation

Company may have erroneously been operating under a generic classification

New company is to be known as QuintilesIMS

Drug dispensing, point of care testing and diagnostics are beneficiaries

Drug Channel’s analysis of Inc. 5000 shows some eye-popping growth

CIS by Deloitte seeks to provide a comprehensive service for revenue management

Mylan CEO sticks to authorized-generic strategy for price relief

Roche could overtake Novartis as the No. 1 global firm by then, says Evaluate Pharma

Pharmacy benefit managers feel some marketplace heat even as they establish new benefit programs

Walgreens-Rite Aid merger is still pending

EpiPen controversy has a new twist: paying lower rebates to state Medicaid programs

Sponsored by TGaS Advisors

Presidential politicking adds momentum to the growing backlash, and not just for Mylan

Healthcare research firm calls out the alarmist predictions over PCSK9s and other new drugs

CROs are expanding their scope of services

Deal deepens Teva’s business in generics

Advent joins Thomas Lee Partners in ownership of the clinical, commercial outsourcer

GE Healthcare makes a key acquisition in cell culture production technology

Technology projects, M&A and reimbursement questions drive growth

The annual Operation Pangea nets a next crop of crooks; consumer groups raise awareness

A repeat of the +6.5% cost trend indicates that medical costs are still rising above inflation

Internationalization of drug wholesaling is a factor in the name change

Branded products are 92% US market in dollar value, says IMS Institute

Bloomberg BusinessWeek rakes over charitable copay programs